Global Gene Expression Profile of Human Cord Blood–Derived CD133+ Cells

Abstract

Human cord blood (CB)-derived CD133؉ cells carry characteristics of primitive hematopoietic cells and proffer an alternative for CD34 ؉ cells in hematopoietic stem cell (HSC) transplantation. To characterize the CD133 ؉ cell population on a genetic level, a global expression analysis of CD133 ؉ cells was performed using oligonucleotide microarrays. CD133؉ cells were purified from four fresh CB units by immunomagnetic selection. All four CD133؉ samples showed significant similarity in their gene expression pattern, whereas they differed clearly from the CD133 ؊ control samples. In all, 690 transcripts were differentially expressed between CD133؉ and CD133 ؊ cells. Of these, 393 were increased and 297 were decreased in CD133 ؉ cells. The highest overexpression was noted in genes associated with metabolism, cellular physiological processes, cell communication, and development. A set of 257 transcripts expressed solely in the CD133 ؉ cell population was identified. Colonyforming unit (CFU) assay was used to detect the clonal progeny of precursors present in the studied cell populations. The results demonstrate that CD133؉ cells express primitive markers and possess clonogenic progenitor capacity. This study provides a gene expression profile for human CD133 ؉ cells. It presents a set of genes that may be used to unravel the properties of the CD133 ؉ cell population, assumed to be highly enriched in HSCs. STEM CELLS 2006;24: 631-641

The integrin 9 1 on hematopoietic stem and progenitor cells: involvement in cell adhesion, proliferation and differentiation

“…Recent findings by Jaatinen and co-workers, 30 who detected integrin α9 chain transcripts in a microarray analysis of human CD133…”

Identification of key genes responsible for cytokine-induced erythroid and myeloid differentiation and switching of hematopoietic stem cells by RAGE

“…Recently, oligonucleotide microarrays were used for the gene expression profiling of untreated CD133 + HSCs (CD133 + vs CD133 -) [33,34]. Both studies used the same Figure 6 Comparison mapping of genes expressed in erythroid and myeloid development and differentiation to biological processes.…”

“…npg procedures for enrichment of CD133 + cells, purification of RNA, amplification and labeling of RNA probes, and almost the same oligonucleotide microarrays (HG-U133A from Affymetrix), GeneChip scanners, and GeneChip operating software for data analyses. One study identified 690 differentially expressed genes and another identified 584 differentially expressed genes; however, some were inconsistent between these two studies [33,34]. Here, we analyzed the expression patterns of gene, protein and cell surface antigen, and the biological process of the related genes in erythroid and myeloid differentiation and switching of CD133 + HSCs in response to EPO and G-CSF.…”

Musashi2 sustains the mixed-lineage leukemia–driven stem cell regulatory program

“…We found 50 gene sets that were enriched for downregulated genes in Msi2 Δ/Δ LSCs and 233 gene sets that were enriched in genes upregulated in Msi2 Δ/Δ LSCs (Supplemental Tables 4 and 5). The top ranked gene sets in the Msi2 Δ/Δ LSCs included enrichment in genes that are downregulated in LSCs (33) and HSCs (39) and genes upregulated during myeloid differentiation (ref. 40 and Figure 4, B-D).…”